Healthy Aging for Men in Their 50s

Your 50s often bring the first health surprises: a number that’s crept up, a screening letter, a friend’s diagnosis. It’s the decade when the risks that shape living longer and better shift from mostly accidental to mostly chronic, and when several new checks come due. Humanic Blue focuses here on what changes in your 50s, rather than replaying every earlier health checklist.

In final 2024 US data, heart disease, cancer and unintentional injury were the three leading causes of death among men ages 55 to 64, followed by diabetes and chronic liver disease. The decade adds new decisions to the ones started in your 40s. People with the qualifying smoking history may begin yearly lung cancer screening at 50. The US Preventive Services Task Force (USPSTF) begins its individual decision window for the prostate-specific antigen (PSA) blood test at 55, while the American Cancer Society starts the average-risk discussion at 50. The CDC recommends shingles and routine pneumococcal vaccination beginning at 50, with the latter depending on previous doses. Heart risk, blood sugar, blood pressure and colorectal screening continue.

What follows focuses on what’s new in the 50s. The foundations from the previous decade are in Healthy Aging for Men in Their 40s.

How do the risks shift in your 50s?

The ranking comes from the National Center for Health Statistics’ final 2024 report and is specific to US males of all races and origins.

At ages 45 to 54, heart disease leads, followed by injury, cancer, suicide and chronic liver disease. At 55 to 64, heart disease and cancer pull far ahead, followed by injury, diabetes and chronic liver disease. The exact counts are in Extra Insights. Rankings depend on the age band and eligible cause categories, and counts partly reflect differences in the size and mortality rate of each age group.

Which cancer-screening decisions are new in your 50s?

Lung cancer screening, if you smoked. The USPSTF recommends annual low-dose computed tomography (CT), an X-ray scan, from ages 50 to 80 for people with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years. Screening stops after 15 smoke-free years or when health limits life expectancy or willingness or ability to undergo curative lung surgery. A pack-year is one pack a day for a year, so 20 pack-years could mean one pack daily for 20 years or two packs daily for 10. Eligibility starts a shared decision, not an automatic scan: potential harms include false alarms, unrelated findings that lead to further tests, detection of cancers that would never cause illness (overdiagnosis), and radiation exposure.

Prostate: the decision window opens. The USPSTF recommends an individual PSA-screening decision from ages 55 to 69 after discussing benefits and harms. That 2018 recommendation is being updated. The American Cancer Society advises the discussion at 50 for average-risk men expected to live at least ten more years, and earlier for higher-risk men, as covered in the 40s article.

Colorectal: continue. Screening that started at 45 continues through 75 for average-risk adults under USPSTF guidance, as covered in What Health Screenings Do You Need in Your 40s?

Which eligibility differences separate lung, colorectal and prostate screening in this decade?

Heart disease and diabetes: still the core numbers

Heart-disease deaths were about two and a half times as numerous in the older male age band, but those counts from two different age groups are not an individual’s rate of change. The measurements that guide prevention stay the same: blood pressure, blood fats such as cholesterol, diabetes risk and the complete cardiovascular picture. The 2026 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline uses the PREVENT calculator to estimate cardiovascular risk in adults 30 to 79 and recommends measuring lipoprotein(a), or Lp(a), an inherited blood-fat particle linked to cardiovascular risk, at least once in adulthood. The USPSTF retains separate 2022 guidance on statins, medicines that lower cholesterol, for adults 40 to 75 with a risk factor, offering treatment at 7.5% to under 10% ten-year risk and recommending it at 10% or higher. Which approach applies is a clinical decision, not a verdict from age alone. Which tests to get is covered in What Blood Tests Should I Get for Longevity?

The 2024 Princeton IV consensus treats erectile dysfunction as a cardiovascular risk marker, although it does not establish the cause in one man. That is covered in Is Erectile Dysfunction a Sign of Heart Disease?

Lungs, sleep and bones

Chronic lung disease ranks seventh among men ages 55 to 64. The USPSTF recommends against screening adults without symptoms for chronic obstructive pulmonary disease (COPD), a group of long-term conditions that restrict airflow. That does not apply to chronic cough, sputum, shortness of breath or wheezing, which warrant clinical evaluation. Lung-function testing for symptoms is different from low-dose CT screening for lung cancer.

Sleep apnea, repeated pauses in breathing during sleep. Using overnight sleep testing in employed Wisconsin adults and applying the results to 2007–2010 US weight distributions, researchers estimated moderate-to-severe sleep-disordered breathing in 17% of men ages 50 to 70 versus 10% at ages 30 to 49. Those estimates are modeled, regional and now dated. Loud snoring, witnessed pauses and daytime sleepiness are reasons to ask about evaluation.

Bones. Men generally lose bone more slowly than women, but the Bone Health and Osteoporosis Foundation advises discussing bone-density testing after a fracture at age 50 or older. The 2025 USPSTF found evidence insufficient to recommend routine population screening for men, so a fracture or another clinical risk can change whether testing is considered. That’s covered in Protect Bone Density as You Age.

What distinguishes symptom evaluation from screening in the guidance for lungs, sleep and bones?

Which vaccines come due in your 50s?

The current CDC adult schedule lists two doses of the shingles vaccine (recombinant zoster vaccine) beginning at 50. The CDC explains that pneumococcal vaccines help protect against infections caused by pneumococcal bacteria, including pneumonia, bloodstream infection and meningitis (infection of the lining around the brain and spinal cord). They do not cover every cause of pneumonia. It also recommends routine pneumococcal vaccination from 50 for adults who have not previously received an indicated pneumococcal conjugate vaccine; the vaccine product and whether another type of pneumococcal vaccine, PPSV23, is needed later depend on vaccination history. Other vaccines depend on health conditions, prior doses and the current schedule, and the schedule accounts for previous doses rather than automatically restarting completed series. A clinician or pharmacist can check that history.